These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 7566519)

  • 1. Are there any differences in the safety and efficacy of brofaromine and imipramine between non-elderly and elderly patients with major depression?
    Volz HP; Müller H; Möller HJ
    Neuropsychobiology; 1995; 32(1):23-30. PubMed ID: 7566519
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brofaromine in elderly major depressed patients--a comparative trial versus imipramine.
    Möller HJ; Volz HP
    Eur Neuropsychopharmacol; 1993 Dec; 3(4):501-10. PubMed ID: 8111223
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brofaromine versus imipramine in in-patients with major depression--a controlled trial.
    Volz HP; Gleiter CH; Möller HJ
    J Affect Disord; 1997 Jul; 44(2-3):91-9. PubMed ID: 9241569
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brofaromine in depression: a Canadian multicenter placebo trial and a review of standard drug comparative studies.
    Chouinard G; Saxena BM; Nair NP; Kutcher SP; Bakish D; Bradwejn J; Kennedy SH; Sharma V; Remick RA; Kukha-Mohamad SA
    Clin Neuropharmacol; 1993; 16 Suppl 2():S51-4. PubMed ID: 8313397
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of initial treatment with antidepressants as a predictor of outcome after 8 weeks.
    Volz HP; Müller H; Sturm Y; Preussler B; Möller HJ
    Psychiatry Res; 1995 Sep; 58(2):107-15. PubMed ID: 8570762
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brofaromine in major depressed patients: a controlled clinical trial versus imipramine and open follow-up of up to one year.
    Möller HJ; Volz HP
    J Affect Disord; 1992 Nov; 26(3):163-72. PubMed ID: 1460166
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brofaromine in non-endogenous major depressed inpatients--results of a preliminary dose-finding trial versus tranylcypromine.
    Volz HP; Heimann H; Bellaire J; Laux G; Möller HJ
    Pharmacopsychiatry; 1994 Jul; 27(4):152-8. PubMed ID: 7972347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monoamine oxidase inhibitors in resistant major depression. A double-blind comparison of brofaromine and tranylcypromine in patients resistant to tricyclic antidepressants.
    Nolen WA; Haffmans PM; Bouvy PF; Duivenvoorden HJ
    J Affect Disord; 1993 Jul; 28(3):189-97. PubMed ID: 8408980
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential response patterns to MAO inhibitors and tricyclics.
    Nies A
    J Clin Psychiatry; 1984 Jul; 45(7 Pt 2):70-7. PubMed ID: 6376487
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How to assess the onset of antidepressant effect: comparison of global ratings and findings based on depression scales.
    Möller HJ; Müller H; Volz HP
    Pharmacopsychiatry; 1996 Mar; 29(2):57-62. PubMed ID: 8741022
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of reversible inhibitors of monoamine oxidase-A in various forms of depression.
    Lecrubier Y; Guelfi JD
    Acta Psychiatr Scand Suppl; 1990; 360():18-23. PubMed ID: 2248063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic and side-effect profile of a selective and reversible MAO-A inhibitor, brofaromine. Results of dose-finding trials in depressed patients.
    Schiwy W; Heath WR; Delini-Stula A
    J Neural Transm Suppl; 1989; 28():33-44. PubMed ID: 2677240
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The pharmacotherapy of minor depression.
    Stewart JW; Quitkin FM; Klein DF
    Am J Psychother; 1992 Jan; 46(1):23-36. PubMed ID: 1543251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of brofaromine in depression: a Canadian multicenter placebo controlled trial and a review of comparative controlled studies.
    Chouinard G; Saxena BM; Nair NP; Kutcher SP; Bakish D; Bradwejn J; Kennedy SH; Sharma V; Remick RA; Kukha-Mohamad SA
    Clin Neuropharmacol; 1992; 15 Suppl 1 Pt A():426A-427A. PubMed ID: 1498901
    [No Abstract]   [Full Text] [Related]  

  • 15. Reboxetine versus imipramine in the treatment of elderly patients with depressive disorders: a double-blind randomised trial.
    Katona C; Bercoff E; Chiu E; Tack P; Versiani M; Woelk H
    J Affect Disord; 1999 Oct; 55(2-3):203-13. PubMed ID: 10628889
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brofaromine in treatment-resistant depressed patients--a comparative trial versus tranylcypromine.
    Volz HP; Faltus F; Magyar I; Möller HJ
    J Affect Disord; 1994 Mar; 30(3):209-17. PubMed ID: 8006247
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of a reversible monoamine oxidase-A inhibitor versus imipramine in subgroups of depressed patients.
    Bizière K; Berger M
    Acta Psychiatr Scand Suppl; 1990; 360():59-60. PubMed ID: 2248074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and tolerability of St. John's wort extract LI 160 versus imipramine in patients with severe depressive episodes according to ICD-10.
    Vorbach EU; Arnoldt KH; Hübner WD
    Pharmacopsychiatry; 1997 Sep; 30 Suppl 2():81-5. PubMed ID: 9342765
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Moclobemide--placebo-controlled trials.
    Silverstone T
    Int Clin Psychopharmacol; 1993 Jan; 7(3-4):133-6. PubMed ID: 8468433
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reversible monoamine oxidase-A inhibitors in resistant major depression.
    Nolen WA; Hoencamp E; Bouvy PF; Haffmans PM
    Clin Neuropharmacol; 1993; 16 Suppl 2():S69-76. PubMed ID: 8313400
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.